Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced that Interim Chief Executive Officer Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event is scheduled for June 4, 2026, at 2:35 p.m. EDT in New York. The discussion will be webcast live, with a replay available through the Events & Presentations section of the company's investor relations website. This participation provides Helus Pharma with a platform to discuss its pipeline and clinical progress with investors and industry experts.
The company is currently advancing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004 is in Phase 2 for generalized anxiety disorder. Helus Pharma's NSAs are designed to activate serotonin pathways believed to promote neuroplasticity, addressing significant unmet needs in depression, anxiety, and other mental health conditions. The company's approach aims to provide durable improvements in mental health through its proprietary synthetic molecules.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, operates in Canada, the United States, the United Kingdom, and Ireland. The company has an extensive research portfolio of investigational NSAs beyond its lead candidates. For more details on the company's pipeline and updates, interested parties can visit helus.com or follow the team on X, LinkedIn, YouTube, and Instagram. The full press release regarding the conference participation is available at https://ibn.fm/1QdP7.
The Jefferies Global Healthcare Conference is a key event for the healthcare investment community, and Helus Pharma's involvement underscores its commitment to advancing its clinical programs and engaging with stakeholders. The fireside chat offers an opportunity for the company to highlight its progress and future directions in developing treatments for mental health disorders.
